Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-naïve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.Keywords: bevacizumab (Avastin®), interferon alpha, efficacy, tolerability, renal cell carcinoma (RCC), low-dose interferon |
|---|